Eric Lefkofsky, Founder and CEO of Tempus, shared a post on LinkedIn:
“The NCCN’s update to pancreatic cancer guidelines is a significant moment for precision medicine. It’s a move toward a reality where each and every patient’s treatment plan is defined by their specific biology.
By standardizing NGS and RNA sequencing, the clinical guidelines are finally aligning with the multimodal approach we’ve pioneered at Tempus to ensure life-changing targeted therapies are accessible to those previously invisible to traditional diagnostics.”
Other articles featuring Eric Lefkofsky on OncoDaily.